Gastrointestinal Therapeutics Market Outlook 2031
The Global Gastrointestinal therapeutics market size was valued at USD 37.60 Billion in 2022 and is likely reach to USD 50.36 Billion by 2031, expanding at a CAGR of 3.3% during the forecast period, 2023–2031.
The growth of the market is attributed to the increasing demand for biologic gastrointestinal disorders treatment, rising occurrence of gastrointestinal diseases caused by unhealthy life style, and ongoing clinical trials with appropriate outcomes in the market.
Gastrointestinal syndrome normally affects the functioning of organs in the digestive area such as pancreas, stomach, small & large intestines, liver, and gall bladder. Constipation indigestion, bloating, and heartburn are some major symptoms of gastrointestinal syndrome.
Gastrointestinal therapeutics include the applications of both over-the-counter drugs and prescription drugs that involve the use of various testing processes such as antidiarrheal agents, antiulcer agents, antacids, laxatives, antiemetics, endoscopic radiological procedures, and hematological tests.
These therapeutics are performed to detect the disorder and absorb nutrients from the food to improve digestion, reducing gastric acidity, and regulate water flow in the gastrointestinal system.
The Integrated Global Action Plan for Diarrhea by the World Health Organization and United Nations Children’s Emergency Fund are two key programs emphasizing on minimizing childhood mortality caused by diarrhea.
These programs also offer various campaigns by providing interventions and services to raise awareness and provide access to treatment & precautionary measures.
According to a study published in the BMC Journal in August 2020 by Thomas Joshua Pasvol et al., the incidence of ulcerative colitis, Crohn's disease, and inflammatory bowel disease in the United Kingdom was found to be 28.6, 10.2, and 15.7 per 100,000 people respectively.
As per a study published in the Digestive Diseases Journal in March 2021 by Hunt R.H.a et al., the SARS-CoV-2 virus can have a major impact on the digestive system as the virus can damage several organs including liver and stomach.
Some repurposed medications used to treat the virus can cause COVID-19-related gastrointestinal symptoms as well as liver injury.
Market Trends, Drivers, Restraints, and Opportunities
- Increasing R&D programs and development of innovation therapeutic products are key factors boosting the market growth.
- Rising prevalence of gastrointestinal disorders globally due to the expanding geriatric population and unhealthy food habits among people is fueling the growth of the market.
- Increasing health consciousness among people and improvements in the healthcare infrastructure in developing countries are anticipated to drive the market expansion.
- High chances of side effects and low diagnosis rates along with rising price erosion are major factors restraining the market growth.
- Ongoing awareness campaigns and favorable government rules & regulation are expected to give better opportunities for propelling the market growth in the coming future.
Scope of Gastrointestinal Therapeutics Market Report
The report on the global gastrointestinal therapeutics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Gastrointestinal Therapeutics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Drugs (Antacids, Laxatives, Antidiarrheal agents, Antiemetic, H2 Antagonists, Biologics, Enzyme Replacement Therapies, Proton-pump Inhibitors, and Aminosalicylates), Dosages (Oral, Intravenous, and Others), Applications (Ulcerative Colitis, Irritable Bowel Syndrome, Crohn's Disease, Celiac Disease, and Gastroenteritis), and Distribution Channels (Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Valeant Pharmaceuticals; Allergan plc; Abbott Laboratories; Takeda Pharmaceutical Company Ltd.; Abbvie Inc.; Bayer AG; and Cipla Inc.
|
Gastrointestinal Therapeutics Market Segment Insights
Ulcerative colitis segment is expected to expand at a rapid pace
Based on applications, the global gastrointestinal therapeutics market is segregated as ulcerative colitis, irritable bowel syndrome, crohn's disease, celiac disease, and gastroenteritis. The ulcerative colitis segment is expected to expand at a rapid pace during the forecast period owing to the ease of availability of drugs in the market for the treatment of gastrointestinal syndrome.
Moreover, increasing occurrence prognosis and rising cases of disorders related to unhealthy food eating habit are anticipated to boost the disease recurrence.
Intravenous segment is projected to expand at a considerable rate
On the basis of dosages, the market is segmented into oral, intravenous, and others. The intravenous segment is projected to expand at a significant rate in the coming years due to the easy administration and cost efficiency factors. Moreover, wide adoption of the dosage for the treatment purposes is a key factor fueling the segment growth.
On the other hand, the oral segment is projected to grow substantially in the near future attributing to the direct contact with the afflicted areas, oral gastrointestinal medicines have a better effectiveness. However, other methods such as intravenous and transdermal offer higher absorption as compared to oral medicines, which acts as a key challenge for the segment growth.
Retail pharmacies segment is estimated to register a high CAGR
Based on distribution channels, the global gastrointestinal therapeutics market is divided into retail pharmacies, hospital pharmacies, and online pharmacies. Due to the great affordability and accessibility of retail pharmacies, the retail pharmacies segment is estimated to register a high CAGR during the forecast period.
Rising recommendation from medical practitioners and their encouragement to patients to purchase medicines from retail pharmacies as the number of prescription drugs are being increasingly reimbursed present a major factor for the segment growth.
Drug replacements that avoid hazardous drug interactions are also recommended by retail pharmacists.
Gastrointestinal Therapeutics Market Regional Outlook
North America is anticipated to constitute a key market share
In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a key market share during the forecast period due to rising cases of health conditions related to unhealthy lifestyle, causing a large number of cases of gastrointestinal diseases.
Europe, on the other hand, is anticipated to register considerable growth in the coming years owing to the presence of key regional players with the establishment of strong product portfolio in this region.
Meanwhile, the market of Asia Pacific is expected to grow at an exponential rate during the forecast period owing to the ongoing efforts made by regional companies including R&D investments and the marketing of branded pharmaceuticals at a low cost.
Segments
Drugs
- Antacids
- Laxatives
- Antidiarrheal agents
- Antiemetic
- H2 Antagonists
- Biologics
- Enzyme Replacement Therapies
- Proton-pump Inhibitors
- Aminosalicylates
Dosages
Applications
- Ulcerative Colitis
- Irritable Bowel Syndrome
- Crohn's Disease
- Celiac Disease
- Gastroenteritis
Distribution Channels
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Valeant Pharmaceuticals
- Allergan plc
- Abbott Laboratories
- Takeda Pharmaceutical Company Ltd.
- Abbvie Inc.
- Bayer AG
- Cipla Inc.
Competitive Landscape
Major companies competing in the market are Valeant Pharmaceuticals; Allergan plc; Abbott Laboratories; Takeda Pharmaceutical Company Ltd.; Abbvie Inc.; Bayer AG; and Cipla Inc. These market players have actively involved in competition sustainability strategies such as new product development and distribution channel expansion to get a larger share of the market.
Furthermore, a greater emphasis on refining operations and supply chain management are expected to constitute a key market share in coming years.
Janssen Research & Development, LLC. has launched a phase III clinical trial in March 2021 to assess the safety and efficiency of ustekinumab in children with moderately to severe Crohn's disease. Pizensy (lactitol) was approved by the United States Food and Drug Administration in March 2020 for the treatment of chronic idiopathic constipation in adults.
Pizensy is an osmotic laxative that works by producing influx of water into the small intestine, causing the laxative effect in the colon.
Mitsubishi Tanabe Pharma has signed an exclusive licensing deal with Salix Pharmaceuticals to commercialize and develop late-stage experimental S1P modulators for the treatment of inflammatory bowel disease in 2019.
Request For Customization
Enquiry Before Buying
Speak With Analyst
